Parnassus Investments, an investment management company, released the "Parnassus Growth Equity Fund" second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index's 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services and Financials holdings detracted. For the year-to-date period, the Fund returned 6.17% (net of fees), outperforming the Russell 1000 Growth's 5.33%. The firm remains constructively bullish on U.S. equities and continues to be selective, valuation-sensitive, and focused on disruptive growth opportunities through active stock selection. Growth stocks advanced during the second quarter, as the Russell 1000 Growth Index generated strong double-digit returns driven by increased confidence in the durability of the ongoing artificial intelligence (AI) infrastructure build-out. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Parnassus Growth Equity Fund highlighted Revolution Medicines, Inc. (NASDAQ:RVMD) as a new addition. Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. On September 15, 2026, Revolution Medicines, Inc. (NASDAQ:RVMD) closed at $204.86 per share. Over the past month, Revolution Medicines, Inc. (NASDAQ:RVMD) declined 6.53% and its shares gained 358.00% over the past 52 weeks. Revolution Medicines, Inc. (NASDAQ:RVMD) has a market capitalization of $43.91 billion.
Parnassus Growth Equity Fund stated the following regarding Revolution Medicines, Inc. (NASDAQ:RVMD) in its Q2 2026 investor letter:
"In the Health Care sector, we see compelling long-term idiosyncratic growth opportunities in drug discovery, diagnostics and medical innovation. During the quarter, we added Revolution Medicines, Inc. (NASDAQ:RVMD), developer of a promising new drug for pancreatic cancer. Revolution Medicines' lead drug candidate, daraxonrasib, has delivered strong late-stage clinical results in pancreatic cancer, with data suggesting it could become a new standard of care and support significant commercial potential, alongside additional opportunities in other cancers over time."
Revolution Medicines, Inc. (NASDAQ:RVMD) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 105 hedge fund portfolios held Revolution Medicines, Inc. (NASDAQ:RVMD) at the end of the second quarter, compared to 106 in the previous quarter. While we acknowledge the potential of Revolution Medicines, Inc. (NASDAQ:RVMD) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Tr